Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluation of the Clinical Benefit of a Transmitter for Contralateral Routing of Signals (CROS)

8 de abril de 2022 actualizado por: Sonova AG
This study will evaluate the clinical benefit of a transmitter for contralateral routing of signals. The benefit will be evaluated in noisy environments regarding speech intelligibility when the CROS system is adjusted to different microphone settings. Additionally, data regarding overall system stability, crash reboot rate, sound quality and connectivity will be obtained over a period of time to validate the CROS system in combination with smartphone and accessories. This study is a confirmatory study.

Descripción general del estudio

Descripción detallada

Unilateral Hearing Loss (UHL) can be defined as any degree of permanent hearing loss on one ear with normal hearing in the opposite ear. Unilateral hearing loss can be debilitating associated with audiological, psychosocial and educational challenges. Audiological challenges include the reduced ability to localize sounds, reduced awareness on the unaidable side and difficulties hearing in noise or at a distance.

One solution for unaidable UHL is Contralateral Routing of Signals (CROS) and Bilateral Contralateral routing of signals (BiCROS) using a so- called CROS transmitter together with a hearing aid.

The rationale for this clinical investigation is to collect clinical data with a rechargeable CROS transmitter to evaluate the benefits of a BiCROS fitting compared to the alternative treatment option, the monaural hearing aid fitting, and to no treatment in noisy listening situations.

Tipo de estudio

Intervencionista

Inscripción (Actual)

23

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Zürich
      • Stäfa, Zürich, Suiza, 8712
        • Sonova AG

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • hearing impaired adults, with & w/o hearing aids (experiences)
  • good written and spoken (Swiss) German language skills
  • ability to fill in a questionnaire conscientiously
  • informed consent as documented by signature
  • asymmetric hearing loss: one unaidable ear (min. N6 hearing loss) / the other ear with N3 or N4 hearing loss
  • availability of Smartphone
  • availability of TV or Tablet
  • ability to operate and handle the investigational device
  • ability to describe listening impressions/experiences and the use of the hearing aid
  • Ability to produce a reliable hearing test result

Exclusion Criteria:

  • Contraindications to the medical device:
  • aidable hearing loss on the intended CROS side
  • acute tinnitus (in either one ear and occurrence less than three months)
  • anatomical deformity of the CROS ear (e.g. absence of the auricle)
  • Known hypersensitivity or allergy to materials of the investigational device
  • any auricle deformities, that prevents secure placement of the (test) devices
  • no willingness to test the investigational device system
  • no willingness to test the investigational device system for at least 8h a day
  • Hint for psychological problems from investigators point of view
  • reported fluctuating hearing that could influence the test result
  • reported symptoms of vertigo and dizziness by participants

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Speech Intelligibility with CROS device

The focus of this study is on Speech Intelligibility (SI), evaluated by the Oldenburg Sentence test (OLSA), which measures a speech recognition threshold (SRT) in dB SNR (signal to noise ratio).

Therefore each participant will perform the tests with the experimental rechargeable CROS transmitter (CROS) in different interventions, like comparison to monaural fitting and unaided condition.

All participants will perform the same tests. The order of the intervention in the speech test is randomized, but will be performed in the same visit by each participant.

Sin tratamiento, es decir, los participantes no están equipados con un dispositivo CROS y/o audífono.

La condición sin ayuda actúa como intervención de control.

Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible hearing device on the other ear.

Each participant will be fitted with a hearing aid on the better hearing ear and no device on the poorer, unaidable ear.

Monaural hearing aid fitting acts as control intervention.

Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible device on the other ear. The difference to the BiCROS condition is the setup of the microphones in the CROS device and the compatible hearing device.

This test condition is only tested for speech intelligibility in diffuse noise and acts as control intervention.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Speech Intelligibility (SI) in noise (fix direction): BiCROS fitting vs. monaural hearing aid fitting
Periodo de tiempo: 2 weeks

The primary objective of this clinical investigation is to evaluate whether a BiCROS fitting (better ear fitted with a hearing device, unaidable ear supplied with a CROS device) improves speech intelligibility in noise compared to a monaural fitting (just the aidable ear is supplied by a hearing aid), for adults with an asymmetric hearing loss, measured with the Oldenburg Sentence Test (OLSA). Results of the speech test will be the SRT (speech recognition threshold) in dB SNR (signal to noise ratio).

The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
SI in noise (fix direction): BiCROS fitting vs. unaided
Periodo de tiempo: 2 week

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility in noise compared to an unaided condition, for adults with an asymmetric hearing loss, measured with the Oldenburg Sentence Test (OLSA).

Results of the speech test will be the SRT (dB SNR). The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 week
SI in diffuse noise: BiCROS fitting vs. monaural fitting
Periodo de tiempo: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility by at least 1 dB SNR for 50% SRT in diffuse noise, compared to a monaural hearing aid fitting.

The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: BiCROS fitting vs. unaided
Periodo de tiempo: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility by at least 1 dB SNR for 50% SRT in diffuse noise, compared to an unaided condition.

The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: BiCROS vs. CROS baseline fitting
Periodo de tiempo: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a BiCROS fitting improves speech intelligibility in diffuse noise compared with a CROS baseline fitting. CROS baseline means a fitting of an additional program with different hearing instrument microphone setup.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: CROS baseline fitting vs. unaided
Periodo de tiempo: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a CROS baseline fitting improves speech intelligibility in diffuse noise compared with an unaided condition.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SI in diffuse noise: CROS baseline fitting vs. monaural fitting
Periodo de tiempo: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a CROS baseline fitting improves speech intelligibility in diffuse noise compared with a monaural fitting.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
SP in diffuse noise: monaural fitting vs. unaided
Periodo de tiempo: 2 weeks

A secondary objective of this clinical investigation is to evaluate whether a monaural fitting improves speech intelligibility in diffuse noise compared with an unaided condition.

The SI will be tested with the OLSA in diffuse noise. The target speaker will be presented from 0° azimuth and is adaptive (start level at 65dB (A).

The noise will be presented on the better ear at an azimuth of 90° or 270° (depending on the site of the better ear), at a level of 70 dB (A).

2 weeks
Evaluation of Sound quality
Periodo de tiempo: 3 weeks

A secondary objective of this study is to evaluate the participant's satisfaction of the sound quality of the experimental CROS device by a subjective rating during a three-week home trial period.

Scale: very unsatisfied- unsatisfied- neither nor- satisfied- very satisfied

3 weeks
Evaluation of System stability
Periodo de tiempo: 3 weeks

A secondary objective of this study is to evaluate the participant's satisfaction of the system stability of the experimental CROS device during a three-week home trial period.

The participant shall report, if there are artefacts audible: never/ 1-2 times a week/ 3-6 times a week/ daily

3 weeks
Evaluation of streaming
Periodo de tiempo: 3 weeks

A secondary objective of this study is to evaluate the participant's satisfaction of the streaming sound quality of the experimental CROS device, by a subjective rating during a three-week home trial period.

Scale: very unsatisfied- unsatisfied- neither nor- satisfied- very satisfied

3 weeks
Evaluation of listening effort
Periodo de tiempo: 3 weeks

A secondary objective is to evaluate the subjective listening effort in noise reported by the participant whilst wearing the experimental CROS device.

Scale: not at all - slightly - somewhat - moderately - very - extremely

3 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de octubre de 2021

Finalización primaria (Actual)

14 de marzo de 2022

Finalización del estudio (Actual)

14 de marzo de 2022

Fechas de registro del estudio

Enviado por primera vez

22 de octubre de 2021

Primero enviado que cumplió con los criterios de control de calidad

22 de octubre de 2021

Publicado por primera vez (Actual)

3 de noviembre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

15 de abril de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

8 de abril de 2022

Última verificación

1 de noviembre de 2021

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir